⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852901 | 0.97 | KDM4E (0.31) | — | |
| SCHEMBL9785084 | 0.79 | HTR1A (0.39) | — | |
| SCHEMBL3585120 | 0.79 | HRH3 (0.33) | — | |
| SCHEMBL9785053 | 0.77 | GNAI3 (0.31) | — | |
| SCHEMBL4314046 | 0.77 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL9784994 | 0.74 | HRH3 (0.33) | — | |
| SCHEMBL4635558 | 0.71 | — | — | |
| SCHEMBL4723749 | 0.69 | — | — | |
| SCHEMBL1269153 | 0.69 | KDM4E (0.32) | — | |
| SCHEMBL4722164 | 0.67 | KDM4E (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | claimed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | claimed |
| EP-2121598-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-11-25 | — | — | EP | claimed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | claimed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | claimed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | claimed |
| EP-1633743-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | Amgen, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1631542-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | Amgen, Inc. (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | claimed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | claimed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | disclosed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| EP-1337523-A2 | 2,4-SUBSTITUTED PYRIDINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2003-08-27 | — | — | EP | disclosed |
| US-6559163-B2 | Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression | NEUROGEN CORPORATION | 2003-05-06 | — | — | US | disclosed |
| US-20020161008-A1 | 2,4-Substituted pyridine derivatives | NEUROGEN CORPORATION | 2002-10-31 | — | — | US | disclosed |
| WO-2002014269-A2 | 2,4-SUBSTITUTED PYRIDINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |